ホーム › 肝臓がん（肝細胞がん） › テキサス › Houston
Houston、TXにおける肝臓がん（肝細胞がん）の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、肝臓がん（肝細胞がん）に関する31件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of ZW251 in Participants With Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
被験者募集中第1/2相
- Research Facility, Houston
National Liver Cancer Screening Trial
被験者募集中第4相
- Baylor College of Medicine, Houston
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- The University of Texas Md Anderson Cancer Center, Houston
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
被験者募集中第1/2相
- M D Anderson Cancer Center, Houston
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
被験者募集中第3相
- Research Site, Houston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
被験者募集中第1/2相
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
被験者募集中第1/2相
- Research Site, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- University of Texas MD Anderson Cancer Center, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
被験者募集中第1相
- M D Anderson Cancer Center, Houston
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
被験者募集中第1相
- Clinical Trial Site, Houston
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
被験者募集中
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
被験者募集中第1相
- The University of Texas M. D. Anderson Cancer Center, Houston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
被験者募集中第2相
- M D Anderson Cancer Center, Houston
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
被験者募集中
- M D Anderson Cancer Center, Houston
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
被験者募集中第2相
- USA12-0, Houston
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
被験者募集中第1/2相
- University of Texas MD Anderson Cancer Center, Houston
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
被験者募集中観察研究健康なボランティア歓迎
- M D Anderson Cancer Center, Houston
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
被験者募集中第2相
- Houston Methodist Hospital Cancer Center, Houston
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
被験者募集中第1相
- Oncology Consultants, Houston
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
被験者募集中第2相
- Baylor College of Medicine, Houston
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
被験者募集中第2相
- Houston Methodist Neal Cancer Center, Houston
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
被験者募集中第1相
- Houston Methodist Hospital, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
被験者募集中第4相
- Houston Methodist Research Institute, Houston
他の都市における肝臓がん（肝細胞がん）の試験
- New York City, NY24件の研究
- Dallas, TX19件の研究
- Los Angeles, CA19件の研究
- Boston, MA18件の研究
- Cleveland, OH18件の研究
- Chicago, IL16件の研究
- Philadelphia, PA16件の研究
- Pittsburgh, PA15件の研究
- San Francisco, CA14件の研究
- Orange, CA14件の研究
- Jacksonville, FL14件の研究
- San Antonio, TX13件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。